Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 250.40 as compared to the previous close of Rs. 250.40. The total number of shares traded during the day was 44404 in over 1131 trades.

The stock hit an intraday high of Rs. 255.00 and intraday low of 244.95. The net turnover during the day was Rs. 11101401.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Relonchem MarketingAuthorization OxybutyninHydrochloride OralSolution UKMHRA